Read How Ecolab Performed In Q2

Ecolab Inc ECL reported second-quarter FY22 sales growth of 13% year-on-year to $3.58 billion, beating the consensus of $3.51 billion.
Sales from Global Industrial rose 13%, Global Institutional & Specialty climbed 18%, Global Healthcare & Life Sciences grew 37% Y/Y in fixed currency.
Adjusted EPS of $1.10 beat the analyst consensus of $1.09.
Selling, general and administrative expenses rose 10% Y/Y. The operating margin was 11.9%, and operating income for the quarter fell 5% to $425.8 million.
The company held $124.9 million in cash and equivalents as of June 30, 2022.
Ecolab expects inflation to remain higher for longer and currency translation impacts to become more challenging.
ECL expects 2H overall performance to improve sequentially, though increasing currency translation headwinds will impact full-year earnings.
The company expects Q4 to show accelerating earnings growth, resulting in modest gains in full-year 2022 adjusted EPS.
Price Action: ECL shares are trading lower by 3.06% at $157.92 on the last check Tuesday.